Targeted next generation sequencing identifies clinically actionable mutations in patients with melanoma

Pigment Cell and Melanoma Research

Volumn 27, Issue 4, 2014, Pages 653-663

  Jeck, William R ^a   Parker, Joel ^a   Carson, Craig C ^a   Shields, Janiel M ^a   Sambade, Maria J ^a   Peters, Eldon C ^a   Burd, Christin E ^a   Thomas, Nancy E ^a   Chiang, Derek Y ^a   Liu, Wenjin ^a   Eberhard, David A ^a   Ollila, David ^a   Grilley Olson, Juneko ^a   Moschos, Stergios ^a   Neil Hayes, D ^a   Sharpless, Norman E ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

Clinical trials; Diagnostics; Genomics; Resequencing; Therapeutics

Indexed keywords

B RAF KINASE; B RAF KINASE INHIBITOR; DNA; EPIDERMAL GROWTH FACTOR RECEPTOR 4; LAPATINIB; TUMOR PROTEIN;

ADULT; AGED; ARTICLE; CANCER PATIENT; CLINICAL ARTICLE; COMPARATIVE GENOMIC HYBRIDIZATION; CONTROLLED STUDY; COST; COST EFFECTIVENESS ANALYSIS; DRUG RESPONSE; FEMALE; GENE MUTATION; GENE SEQUENCE; GENETIC VARIABILITY; HIGH THROUGHPUT SEQUENCING; HUMAN; HUMAN CELL; HUMAN TISSUE; INDEL MUTATION; MALE; MELANOMA CELL LINE; METASTATIC MELANOMA; MUTATION RATE; NEXT GENERATION SEQUENCING; SENSITIVITY ANALYSIS; SOMATIC MUTATION; CLINICAL TRIAL; GENETICS; MELANOMA; MUTATION; TUMOR CELL LINE;

CELL LINE, TUMOR; FEMALE; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; MALE; MELANOMA; MUTATION; NEOPLASM PROTEINS;

EID: 84902536316     PISSN: 17551471     EISSN: 1755148X     Source Type: Journal    
DOI: 10.1111/pcmr.12238     Document Type: Article

References (43)

1. Anders, S., and Huber, W. (2010). Differential expression analysis for sequence count data. Genome Biol. 11, R106.
2. Ascierto, P.A., Schadendorf, D., and Berking, C. et al. (2013). MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study. Lancet Oncol. 14, 249-256.
3. Carnahan, J., Beltran, P.J., and Babij, C. et al. (2010). Selective and potent Raf inhibitors paradoxically stimulate normal cell proliferation and tumor growth. Mol. Cancer Ther. 9, 2399-2410.
4. Carson, C., Omolo, B., and Chu, H. et al. (2012). A prognostic signature of defective p53-dependent G1 checkpoint function in melanoma cell lines. Pigment Cell Melanoma Res. 25, 514-526.
5. Cerami, E., Gao, J., and Dogrusoz, U. et al. (2012). The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2, 401-404.
6. Chinnaiyan, A.M., and Palanisamy, N. (2010). Chromosomal aberrations in solid tumors. Prog. Mol. Biol. Transl. Sci. 95, 55-94.
7. Dankort, D., Curley, D.P., Cartlidge, R.A., Nelson, B., Karnezis, A.N., Damsky, W.E., You, M.J., DePinho, R.A., McMahon, M., and Bosenberg, M. (2009). Braf(V600E) cooperates with Pten loss to induce metastatic melanoma. Nat. Genet. 41, 544-552.
8. DePristo, M.A., Banks, E., and Poplin, R. et al. (2011). A framework for variation discovery and genotyping using next-generation DNA sequencing data. Nat. Genet. 43, 491-498.
9. Flaherty, K.T., Puzanov, I., and Kim, K.B. et al. (2010). Inhibition of mutated, activated BRAF in metastatic melanoma. N. Engl. J. Med. 363, 809-819.
10. Forbes, S.A., Bindal, N., and Bamford, S. et al. (2011). OSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer. Nucleic Acids Res., 39 (Database issue), D945-D950.
11. Frampton, G.M., Fichtenholtz, A., and Otto, G.A. et al. (2013). Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing. Nature 31, 1023-1031.
12. 1000 Genomes Project Consortium (2012). An integrated map of genetic variation from 1, 092 human genomes. Nature 491, 56-65.
13. Halaban, R., Zhang, W., Bacchiocchi, A., Cheng, E., Parisi, F., Ariyan, S., Krauthammer, M., McCusker, J.P., Kluger, Y., and Sznol, M. (2010). PLX4032, a selective BRAFV600E kinase inhibitor, activates the ERK pathway and enhances cell migration and proliferation of BRAFWT melanoma cells. Pigment Cell 0. Melanoma Res. 23, 190-200.
14. Hanrahan, A.J., Schultz, N., and Westfal, M.L. et al. (2012). Genomic complexity and AKT dependence in serous ovarian cancer. Cancer Discov. 2, 56-67.
15. Heidorn, S.J., Milagre, C., Whittaker, S., and Nourry, A. (2010). Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF. Cell 140, 209-221.
16. Hodis, E., Watson, I.R., and Kryukov, G.V. et al. (2012). A landscape of driver mutations in melanoma. Cell 150, 251-263.
17. de Hoon, M.J.L., Imoto, S., Nolan, J., and Miyano, S. (2004). Open source clustering software. Bioinformatics 20, 1453-1454.
18. Jackman, D.M., Yeap, B.Y., and Sequist, L.V. et al. (2006). Exon 19 deletion mutations of epidermal growth factor receptor are associated with prolonged survival in non-small cell lung cancer patients treated with gefitinib or erlotinib. Clin. Cancer Res. 12, 3908-3914.
19. Keniry, M., and Parsons, R. (2008). The role of PTEN signaling perturbations in cancer and in targeted therapy. Oncogene 27, 5477-5485.
20. Kim, K.B., Eton, O., and Davis, D.W. et al. (2008). Phase II trial of imatinib mesylate in patients with metastatic melanoma. Br. J. Cancer 99, 734-740.
21. Koboldt, D.C., Chen, K., Wylie, T., Larson, D.E., McLellan, M.D., Mardis, E.R., Weinstock, G.M., Wilson, R.K., and Ding, L. (2009). VarScan: variant detection in massively parallel sequencing of individual and pooled samples. Bioinformatics 25, 2283-2285.
22. Krauthammer, M., Kong, Y., and Ha, B.H. et al. (2012). Exome sequencing identifies recurrent somatic RAC1 mutations in melanoma. Nat. Genet. 44, 1006-1014.
23. Li, H., and Durbin, R. (2009). Fast and accurate short read alignment with Burrows-Wheeler transform. Bioinformatics 25, 1754-1760.
24. Li, J., Lupat, R., Amarasinghe, K.C., Thompson, E.R., Doyle, M.A., Ryland, G.L., Tothill, R.W., Halgamuge, S.K., Campbell, I.G., and Gorringe, K.L. (2012). CONTRA: copy number analysis for targeted resequencing. Bioinformatics 28, 1307-1313.
25. Liu, W., Monahan, K.B., and Pfefferle, A.D. et al. (2012). LKB1/STK11 inactivation leads to expansion of a prometastatic tumor subpopulation in melanoma. Cancer Cell 21, 751-764.
26. Mardis, E.R. (2010). The $1, 000 genome, the $100, 000 analysis? Genome Med. 2, 84.
27. McKenna, A., Hanna, M., and Banks, E. et al. (2010). The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. Genome Res. 20, 1297-1303. Available at: http://genome.cshlp.org/content/early/2010/08/04/gr.107524.110.abstract.
28. Nathanson, K., Martin, A., Letrero, R., D'andrea, K., O'day, S., Infante, J., Falchook, G., Millward, M., Curtis, C., and Gangnon, R. (2011). Tumor genetic analysis of patients with metastatic melanoma treated with the BRAF inhibitor GSK2118436. In ASCO Annual Meeting. Chicago, IL.
29. Nazarian, R., Shi, H., and Wang, Q. et al. (2010). Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nature 468, 973-977.
30. Nollau, P., and Wagener, C. (1997). Methods for detection of point mutations: performance and quality assessment. The IFCC Scientific Division, Committee on Molecular Biology Techniques. Clin. Chem. 43, 1114-1128.
31. Pleasance, E.D., Cheetham, R.K., and Stephens, P.J. et al. (2010). A comprehensive catalogue of somatic mutations from a human cancer genome. Nature 463, 191-196.
32. Prickett, T.D., Agrawal, N.S., Wei, X., Yates, K.E., and Lin, J.C., J.R., Wunderlich, J.C., Cronin, and P., Cruz, Rosenberg, SA, Samuels Y. (2009). Analysis of the tyrosine kinome in melanoma reveals recurrent mutations in ERBB4. Nat. Genet., 41, 1127-1132.
33. Sathirapongsasuti, J.F., Lee, H., Horst, B.A.J., Brunner, G., Cochran, A.J., Binder, S., Quackenbush, J., and Nelson, S.F. (2011). Exome sequencing-based copy-number variation and loss of heterozygosity detection: ExomeCNV. Bioinformatics 27, 2648-2654.
34. Sherry, S.T., Ward, M.H., Kholodov, M., Baker, J., Phan, L., Smigielski, E.M., and Sirotkin, K. (2001). dbSNP: the NCBI database of genetic variation. Nucleic Acids Res. 29, 308-311.
35. Shi, H., Moriceau, G., and Kong, X. et al. (2012). Melanoma whole-exome sequencing identifies (V600E)B-RAF amplification-mediated acquired B-RAF inhibitor resistance. Nat. Commun. 3, 724.
36. Shields, J.M., Thomas, N.E., and Cregger, M. (2007). Lack of extracellular signal-regulated kinase mitogen-activated protein kinase signaling shows a new type of melanoma. Cancer Res. 67, 1502-1512.
37. Stahl, J.M., Cheung, M., Sharma, A., and Trivedi, N.R. (2003). Loss of PTEN promotes tumor development in malignant melanoma. Cancer Res. 63, 2881-2890.
38. Stark, M.S., Woods, S.L., and Gartside, M.G. (2012). Frequent somatic mutations in MAP3K5 and MAP3K9 in metastatic melanoma identified by exome sequencing. Nat. Genet. 44, 165-169.
39. Stones, C.J., Kim, J.E., Joseph, W.R., Leung, E., Marshall, E.S., Finlay, G.J., Shelling, A.N., and Baguley, B.C. (2013). Comparison of responses of human melanoma cell lines to MEK and BRAF inhibitors. Front. Genet. 4, 66.
40. Timmermann, B., Kerick, M., and Roehr, C. et al. (2010). Somatic mutation profiles of MSI and MSS colorectal cancer identified by whole exome next generation sequencing and bioinformatics analysis. PLoS ONE 5, e15661.
41. Trunzer, K., Pavlick, A.C., and Schuchter, L. et al. (2013). Pharmacodynamic effects and mechanisms of resistance to vemurafenib in patients with metastatic melanoma. J. Clin. Oncol. 31, 1767-1774.
42. Wang, K., Li, M., and Hakonarson, H. (2010). ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data. Nucleic Acids Res. 38, e164.
43. Wiedemeyer, W.R., Dunn, I.F., and Quayle, S.N. et al. (2010). Pattern of retinoblastoma pathway inactivation dictates response to CDK4/6 inhibition in GBM. Proc. Natl Acad. Sci. U. S. A. 107, 11501-11506.